Oral Cancer News – Page 186 – The Oral Cancer Foundation News Archive

George Karl takes cancer message to fundraiser in Spokane

Source: www.nba.com Author: Aaron J. Lopez, Nuggets.com Nuggets coach George Karl will be the first person to admit that his fashion sense is more faux pas than je ne sais quoi. He prefers shorts and golf shirts over dress shoes and designer ties, and he often jokes that his clothing choice for the day is determined by what’s on top of the hamper. When it comes to assisting in the fight against cancer, Karl will meet even the strictest of dress codes. Karl, who has survived head and neck cancer and prostate cancer in the past six years, will don a tuxedo this weekend when he serves as the guest speaker at a Coaches vs. Cancer fundraiser in Spokane, Wash. It is the 10th year of the event founded by Gonzaga men’s basketball coach Mark Few and his wife Marcy. “I enjoy speaking about cancer,” Karl said. “It’s become my hobby/ambassadorship, whatever word you want to use. I play amateur sociologist and try to help people become more aware about what is going on.” Karl, 60, has become extremely educated about cancer treatments, research and funding options since recovering from his latest battle over the past 20 months. He is a spokesman for the Cancer Care Initiative at Swedish Medical Center in Englewood and St. Jude Research Hospital in Memphis, Tenn. He also is active with the Cancer League of Colorado and the American Cancer Society. “With all the information and knowledge we have our hands on now, it seems [...]

Oral Cancer Foundation News Team - A2011-08-27T12:38:02-07:00August, 2011|Oral Cancer News|

Rate of HPV Vaccination in Teens Lagging

Source: The Associated Press Author: Staff Only about half of the teenage girls in the U.S. have rolled up their sleeves for a controversial vaccine against cervical cancer — a rate well below those for two other vaccinations aimed at adolescents. The vaccine hit the market in 2006. By last year, just 49 percent of girls had gotten at least the first of the recommended three shots for human papilloma virus, or HPV, a sexually-transmitted bug that can cause cervical cancer and genital warts. Only a third had gotten all three doses, the Centers for Disease Control and Prevention said Thursday. In contrast, the CDC said about two-thirds of teens had gotten the recommended shot for one type of bacterial meningitis and a shot for meningitis and tetanus, diphtheria and whooping cough. Granted, it can take many years for a new vaccine to catch on and reach the 90 percent and above range for many longstanding childhood vaccines. But use of HPV vaccine has been "very disappointing" compared to other newer vaccines, said the CDC's Dr. Melinda Wharton. "If we don't do a much better job, we're leaving another generation vulnerable to cervical cancer later in life," said Wharton. Why aren't more girls getting HPV shots? The vaccine can be very expensive, and it can be a bit of a hassle. It takes three visits to the doctor over six months. But sex no doubt has something to do with it, experts said. Girls are supposed to start the [...]

Charlotte Parker2011-08-26T12:24:52-07:00August, 2011|Oral Cancer News|

New Study for Cancer Patients to Help Improve the Body’s Ability to Fight Illness

Source: Sign On San Diego A Santa Monica research center will test an experimental therapeutic filtering device being developed by Aethlon Medical on blood taken from cancer patients, the San Diego company said Wednesday. The study will target exosomes, bubbles of protein and RNA molecules excreted by cancerous cells that can block immune system cells from fighting the illness. By removing exosomes from circulating blood, Aethlon officials hope their device will improve the body's ability to fight cancer and the effectiveness of treatments such as chemotherapy. Blood taken from 25 patients with non-small cell lung cancer, prostate cancer, melanoma, sarcoma, and head and neck cancer will be circulated through the Hemopurifier device. In clinical use, blood would be filltered directly from the patient and returned to the body in a similar way to kidney dialysis. However, in the newly announced pre-clinical trial blood will not be returned to patients, Aethlon Chairman and Chief Executive Officer James Joyce said. "If we validate that our Hemopurifier is efficient in capturing exosomes, its possible that we could transition towards a human treatment study to evaluate exosome clearance from the entire circulatory system," he said. The test will be conducted by the Sarcoma Oncology Center, a nonprofit independent research institute focused on cancer therapy development. "This clinical histological study is a critical validation step in Aethlon's Hemopurifier strategy for cancer," said Dr. Sant Chawla, the trial's chief investigator. "The concept of 'subtractive therapy', eliminating a major mechanism of tumor progression and resistance to drugs, [...]

Oral Cancer Foundation News Team - A2011-08-25T09:51:41-07:00August, 2011|Oral Cancer News|

Songwriter Nick Ashford Dies; Had Throat Cancer

Source: The New York Times Nick Ashford, who with Valerie Simpson, his songwriting partner and later wife, wrote some of Motown’s biggest hits, like “Ain’t No Mountain High Enough“ and “Ain’t Nothing Like the Real Thing,” and later recorded their own hits and toured as a duo, died Monday at a hospital in New York City. He was 70 and lived in Manhattan. Mr. Ashford had throat cancer and was undergoing treatment, but the cause of his death was not immediately known. His death was announced by Liz Rosenberg, a friend who is a longtime music publicist. One of the primary songwriting and producing teams of Motown, Ashford & Simpson specialized in romantic duets of the most dramatic kind, professing the power of true love and the comforts of sweet talk. In “Ain’t No Mountain High Enough,” from 1967, their first of several hits for Marvin Gaye and Tammi Terrell, lovers in close harmony proclaim their determination that “no wind, no rain, no winter’s cold, can stop me, baby,” but also make cuter promises: “If you’re ever in trouble, I’ll be there on the double.” Gaye and Terrell also sang the duo’s songs “Your Precious Love,” “Ain’t Nothing Like the Real Thing” and “You’re All I Need to Get By.” Diana Ross sang their “Reach Out and Touch Somebody’s Hand,” and when she rerecorded “Ain’t No Mountain High Enough“ in 1970, it became the former Supreme’s first No. 1 hit as a solo artist. “They had magic, and that’s what [...]

Oral Cancer Foundation News Team - A2011-08-24T09:58:06-07:00August, 2011|Oral Cancer News|

Using mouthwash can increase cancer risk for smokers

Source: www.independent.ie Author: Eilish O’Regan, health correspondent Smokers have been warned to stay away from mouthwash – as it might increase their risk of developing mouth cancer. The combination of smoking and drinking alcohol has been established as increasing the risk of the disease. Now researchers have warned that may apply even to the alcohol contained in mouthwash. They pointed out that, while the link between the use of mouthwash containing alcohol and the cancer is not firmly established, it is best avoided or limited in use by smokers. The risk was examined by researchers led by dentist Dr John Reidy and colleagues in the Royal College of Surgeons and St James’s Hospital in Dublin. Around 400 new cases of oral cancer are diagnosed each year in Ireland with two people a week dying from the disease. Symptoms include red and white patches on the lining of the mouth or tongue, a mouth ulcer that does not heal or a swelling that lasts for more than three weeks. The most effective way of preventing mouth cancer is to quit smoking and limit consumption of alcohol, say experts. The researchers said they were concerned about the effects the alcohol in the mouthwash had and it was therefore “prudent” to restrict its use by smokers who are considered “high-risk” for mouth cancer. Around three-quarters of mouth cancers arise due to a patient both smoking and drinking, according to the study in the Journal of the Irish Dental Association. -

Oral Cancer Foundation News Team - A2011-08-24T08:50:11-07:00August, 2011|Oral Cancer News|

Chicago Blackhawks legend Stan Makita optimistic regardless of having mouth cancer

Source: blogs.bettor.com Author: staff Chicago Blackhawks legendary centre player, Stan Mikita, was diagnosed with stage 1 of oral cancer in May of this year, a shocking revelation the former player made through the National Hockey League (NHL) franchise, but luckily, it has termed to be not life-threatening. Since his diagnosis, Mikita, also a Hall of Famer expressed that recently he is beginning to feel much better about the situation and explains it as something which has not hampered his day-to-day activities. He still does everything in his usual manner, something that is more than he could have asked for at the age of 71. “I will know in 10 days how my recovery is when I see the doctor”, Mikita said at the Blackhawks Alumni golf outing named for him at Medinah Country Club. “I’m looking for very favorable comments from him. I might need some work done probably, but I hope it’s not forever. It’s been coming along real well”. Mikita played all 22 seasons of his career in one of the most loyal ways and that was with Chicago Blackhawks. It all began after he was picked up for his performance in the St. Catharines Teepees in the Junior Ontario Hockey Association. He played his first three games during the 1958-1959 season and went on all the way till 1979-1980. Fans who see him in this condition cannot help but ask about the progression. "The best part is, (they ask) 'Are you on skates yet'?" Mikita said, smiling. [...]

Oral Cancer Foundation News Team - A2011-08-24T08:44:05-07:00August, 2011|Oral Cancer News|

Life After Tongue Cancer, & a Total Glossectomy

Source: UCSF Medical Center Author: Sierra Tzoore Tongue cancer is uncommon, and it's especially unusual for it to strike a young person who doesn't smoke or drink heavily. Kate Brown was just 32 years old, recently married and beginning a new job, when she learned that a spot on her tongue was stage III tongue cancer. Brown was referred to UCSF Medical Center, where surgeons recommended a drastic treatment that was her best shot at survival: a total glossectomy, or tongue removal, followed by chemotherapy and radiation. Four years later, Brown is cancer-free and, unlike many patients who undergo total glossectomy, able to eat and speak understandably. We asked Brown about her treatment and path to recovery. How did you discover you had tongue cancer? A small sore appeared on my tongue when I had a sore throat. I took antibiotics for the sore throat, but the spot was still there after the sore throat subsided. I then started to have ear pain and the sore got larger. I was prescribed antibiotics again. When my doctor looked in my ear she didn't see any swelling, but the earache became unbearably painful. I'd never been in pain like that. In my heart of hearts, I knew at that point that something was terribly wrong, but I wasn't sure what it was. I decided to see another doctor, who referred me to an ear, nose and throat specialist, Dr. Ivor Emanuel at California Pacific Medical Center. Dr. Emanuel's specialty is allergies but I think [...]

Charlotte Parker2011-08-22T12:33:47-07:00August, 2011|OCF In The News, Oral Cancer News|

Oral epithelial dysplasia: What does it really mean?

Source: www.rdhmag.com Author: Nancy W. Burkhart, RDH, EdD Patients are sometimes followed for periods of time for what is called dysplasia, leukoplakia, keratotic lesions, and previous frank carcinoma. With any degree of tissue change, the person should be followed closely and an etiology always needs to be determined. Sometimes, removal of a frictional component is suggested; at other times, the lesion may have a more ominous appearance that will alert the clinician that cancer might be high on the differential list. Obviously, in highly suspicious lesions, a biopsy would occur immediately. Patients will sometimes tell the clinician that they were previously biopsied and the report will note "evidence of dysplasia." Sometimes a diagnosis is made of dysplasia, but the lesion becomes carcinoma over time, even after the initial removal of the lesion. The reverse may be true as well, where the body responds physically and the tissue regains a state of health. Why does one individual develop carcinoma while another person may develop a mild epithelial dysplasia? Perhaps the body is able to stop progression or reverse the state of progression. These are questions that researchers continue to evaluate and study. Frictional keratosis, though, is not in the same category as dysplasia. When the frictional component is removed, the lesion will subside. An example of a common lesion that has a frictional component is cheek chewing or morsicatio buccarum. However, chronic frictional or chemical assault on the tissue over time can also cause dysplastic changes. The body has [...]

Oral Cancer Foundation News Team - A2011-08-18T18:12:31-07:00August, 2011|Oral Cancer News|

Dental Care Denied by Medicare Turns into Major Lawsuit

Source: Dr.Bicuspid.com Medicare's refusal to cover extensive dental treatment that is often needed to treat patients with diseases such as oral cancer and Sjögren's syndrome is unreasonable and arbitrary, according to a lawsuit pending in U.S. federal court. The litigation, originally filed in 2008 on behalf of one plaintiff, was recently amended by the Center for Medicare Advocacy (CMA) in the U.S. District Court for the District of Arizona against U.S. Health and Human Services Secretary Kathleen Sebelius on behalf of three Medicare beneficiaries who needed medically related dental care stemming from underlying medical conditions. Medicare policy, which excludes coverage of "routine" dental care, does cover dental services when they are "incident to and an integral part of" eligible medical care. Dental procedures that are covered include extractions in preparation of radiation treatment of neoplastic disease, reconstruction of ridges that are performed simultaneously with the surgical removal of oral tumors, and the wiring of teeth if done in connection with jaw fractures. "We have argued that this is a misinterpretation of the Medicare statute," said CMA attorney Sally Hart, who filed the suit. "We think that beneficiaries who require extensive dental services because of damage from Sjögren's syndrome, as well as cancer radiation treatment and other conditions that destroy the production of saliva, should not fall within the exclusion." CMS does not comment on pending litigation, CMS spokesman Tony Salters told DrBicuspid.com. Why coverage denied Each of the plaintiffs in the CMA lawsuit suffered a serious medical condition, resulting in [...]

Oral Cancer Foundation News Team - A2011-08-16T16:04:15-07:00August, 2011|Oral Cancer News|

Resveratrol Selectively Induces DNA Damage, Independent of Smad4 Expression, in Its Efficacy against Human Head & Neck Squamous Cell Carcinoma

Source: Clinical Cancer Research Author: Robert A. Sclafani, University of Colorado School of Medicine, Campus Box 8101, Room 9100, Aurora, CO 80045. Phone: 303-724-3271; Fax: 303-724-3215; E-mail:[email protected] Abstract Purpose: Alterations in Smad4 signaling and its loss cause genomic instability and head and neck squamous cell carcinoma (HNSCC), suggesting that agents that target both Smad4-dependent and -independent pathways could control HNSCC. Experimental Design: Resveratrol efficacy was evaluated against the HNSCC cells FaDu, Cal27, Det562, and Cal27-Smad4 for viability, DNA damage, cell-cycle progression, and apoptosis, as well as γ-H2AX expression, and focus formation (γ-H2AX and Brca1). Resveratrol efficacy was also examined in nude mice for FaDu xenograft growth. Xenografts were analyzed for γ-H2AX and cleaved caspase-3. Results: Resveratrol (5–50 μmol/L) suppressed viability and induced DNA damage in FaDu and Cal27 cells but not in normal human epidermal keratinocytes and human foreskin fibroblasts, showing its selectivity toward HNSCC cells; however, Det562 cells were resistant to resveratrol even at 100 μmol/L. Cal27 cells stably transfected withSmad4 showed similar resveratrol effects as parental Cal27, indicating that a lack of resveratrol effect in Det562 cells was independent of Smad4 status in these cells. Furthermore, resveratrol caused S-phase arrest and apoptotic death of FaDu and Cal27 cells together with induction of Brca1 and γ-H2AX foci. Resveratrol (50 mg/kg body weight) treatment also inhibited FaDu tumor growth in nude mice, and γ-H2AX and cleaved caspase-3 were strongly increased in xenografts from resveratrol-treated mice compared with controls. Conclusion: Our findings for the first time showed antiproliferative, DNA damaging, and apoptotic effects of resveratrol in [...]

Charlotte Parker2011-08-15T10:20:48-07:00August, 2011|Oral Cancer News|